DeepCure Announces Collaboration with Leeds Institute to Evaluate DC-9476 in Rheumatoid Arthritis
2024年8月19日 - 9:00PM
ビジネスワイヤ(英語)
DeepCure, a therapeutics company using AI to discover novel
drugs for inflammation and immune diseases, today announced a
collaboration with one of the world’s premier research centers for
rheumatoid arthritis (RA), the Leeds Institute of Rheumatic and
Musculoskeletal Medicine (LIRMM). The collaboration will
investigate DC-9476, a third-generation selective BRD4 (BD2)
inhibitor, as a potential treatment for over a million patients
worldwide with RA who do not respond well to current standard of
care.
DC-9476 is a development candidate that inhibits the Brd4
protein which belongs to the BET family of proteins. DC-9476
decreases tissue and blood levels of cytokines that are key
regulators of innate and adaptive immunity, such as TNF-alpha, IL6,
IL-17, and IL-1b, which are up-regulated in autoimmune diseases.
The development candidate is designed to have greater selectivity
for Brd4 and BD2 than previous generations of BET inhibitors to
increase safety. In preclinical RA models, DC-9476 demonstrated
better safety and efficacy compared to RA treatments that are the
standard of care, including TNF-inhibitors and JAK inhibitors.
The experienced team at LIRMM will investigate DC-9476 using
blood samples and joint biopsies from multiple patient subgroups,
in combination with the advanced translational tools developed at
the institute. In particular, the studies will focus on samples
from patients that are classified as difficult to treat or
refractory to current approved therapies. The studies will include
examining gene expression patterns and cytokines measurements in
patient cells and tissues.
“We are thrilled to collaborate with DeepCure on this innovative
project,” said Dr. Kulveer Mankia, Clinical Associate Professor and
Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic
and Musculoskeletal Medicine, Chapel Allerton Hospital. “DC-9476
may represent a novel approach to treating people with RA who have
not responded well to current therapies and have limited treatment
options. We believe these patients could potentially benefit from
DC-9476 due to its activity against multiple immune pathways, and
we are hopeful that this partnership will lead to a significant
breakthrough for patients.”
“We’re excited to work with the clinicians and scientists at
LIRMM and will benefit from their deep expertise in the
complexities of RA and the unmet needs of patients,” said Kfir
Schreiber, CEO & Co-Founder of DeepCure. “This collaboration
allows us to evaluate the efficacy of DC-9476 in patient-derived
samples and help identify RA patient subgroups that will benefit
the most from this compound.”
About DeepCure
DeepCure was founded by researchers at MIT to accelerate
breakthrough therapies using artificial intelligence (AI) and
AI-enabling technologies to innovate small molecule discovery. The
company is based in Boston, MA, and its engineers, chemists, and
biologists collaborate on hard problems to find solutions that will
have an enormous impact on patient health. For more information,
visit www.deepcure.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819183191/en/
Kimberly Ha KKH Advisors kimberly.ha@kkhadvisors.com
917-291-5744